ArticleBiological procedures online2026
MKRN1 suppresses cuproptosis in colorectal cancer through ubiquitin-dependent regulation of SLC31A1.
Article in Biological procedures online, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDespite the emerging role of cuproptosis in cancer biology, the regulatory mechanism by which ubiquitination modulates this process through MKRN1 and SLC31A1 in colorectal cancer (CRC) progression remains unclear. This study aimed to elucidate the functional relationship between MKRN1, SLC31A1, and cuproptosis in CRC.
methodsStable MKRN1-knockdown and MKRN1-overexpressing colorectal cancer (CRC) cell lines were established. Cuproptosis was induced using elesclomol and copper sulfate, and assessed by cell viability assays,, measurement of intracellular copper levels, and western blot analysis of hallmark proteins (HSP70 and DLAT). The MKRN1-SLC31A1 interaction was examined by co-immunofluorescence, ubiquitination assays (employing MG132, CHX, and linkage-specific ubiquitin mutants), and quantitative real-time PCR (q-PCR). Mitochondrial function was evaluated via JC-1 staining and transmission electron microscopy. Rescue experiments were conducted using dual genetic manipulation of MKRN1 and SLC31A1. Finally, in vivo validation was performed using a xenograft model in NOD-SCID mice.
resultsMKRN1 overexpression significantly attenuated cuproptosis agonist-induced cytotoxicity and reduced intracellular copper accumulation. Mechanistically, MKRN1 directly interacts with SLC31A1 and promotes its polyubiquitination and subsequent proteasomal degradation. This degradation prevents copper overload, helping to maintain mitochondrial integrity.(as evidenced by maintained mitochondrial membrane potential and Tomm20 expression) and suppressing key cuproptosis hallmarks, including HSP70 induction and DLAT oligomerization. Genetic rescue experiments confirmed that SLC31A1 knockdown reversed the cuproptosis sensitivity conferred by MKRN1 depletion. Consistently, MKRN1 overexpression promoted tumor growth in vivo while concurrently suppressing cuproptosis.
conclusionIn summary, MKRN1 suppresses copper-induced cell death in colorectal cancer by promoting the ubiquitination and proteasomal degradation of the copper transporter SLC31A1, thus limiting copper accumulation and mitochondrial toxicity. This mechanism confers resistance to copper-induced cell death and facilitates tumor progression, establishing the MKRN1/SLC31A1 axis as a promising therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.